Good catch Bionug.  Yes they do and it covers all indications in China, Hong Kong, Taiwan and Macau.  Reading the last MD&A to refresh my memory...  Newsoara pays milestone payments, they pay for all development costs inside the "Territories" and Zenith gets "sales based milestones and single digit royalties".

Zenith will have to target another chunk of the globe if they are considering another license deal on ZEN-3694.

Newsoara License Agreements In July 2019, Zenith Epigenetics Ltd. entered into a license agreement with Newsoara for our lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau (the “Territories”). Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Territories. If the results from ZEN-3694 are not satisfactory to Newsoara, Newsoara is entitled to replace ZEN-3694 with another of our compounds to which the license agreement will apply, however we would not necessarily develop, market and/or distribute the replacement compound (outside the Territories). Pursuant to the License Agreement, Newsoara agreed to pay Zenith Epigenetics Ltd. upfront and near-term development milestone payments totaling $15.0 million. Initial non-refundable upfront payments of $1.0 million and $2.5 million (less applicable tax withholdings) were received in July and September 2019, respectively. In December 2019, we received a development milestone payment of $5.0 million, less applicable tax withholdings, from Newsoara upon completion of our Phase 2 clinical study with ZEN-3694 in metastatic castration-resistant prostate cancer to Newsoara’s satisfaction and election to continue development. The $7.7 million of unearned licensing revenue at January 31, 2023 is comprised of the upfront payments and development milestone payments (less applicable tax withholdings). Pursuant to the License Agreement, Newsoara also agreed to pay us a $6.5 million development milestone payment for/upon completion of either a Phase 3 clinical trial or a clinical study which results in Zenith receiving accelerated approval by the FDA (subject to Newsoara’s satisfaction with the study’s results). During the year ended April 30, 2021, however, Zenith and Newsoara amended the License Agreement, removing the $6.5 million milestone payment as a condition of the loan from Newsoara. Zenith is eligible to receive tiered royalty payments on sales of products once commercialization commences and Newsoara achieves sales. No amounts have been recognized for these milestone or royalty payments at January 31, 2023 as the conditions described above have not yet been met. 7 In November 2021, Zenith Capital Corp. announced that Zenith Epigenetics Ltd., a wholly-owned subsidiary, had entered into a licensing agreement with Newsoara for Zenith Epigenetics’ lead compound, ZEN-3694, in Asia excluding Middle East and North Africa (“MENA”), India, and ten Eurasian countries (the “Asian Territories”). Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Asian Territories. If the results from ZEN-3694 are not satisfactory to Newsoara, Newsoara is entitled to replace ZEN-3694 with a new compound from the Company to which the license agreement will apply. Zenith received an upfront payment of $3.2 million ($3.5 million less applicable tax withholdings) in November 2021. Zenith will also receive sales-based milestones and single digit royalties.